Beruflich Dokumente
Kultur Dokumente
S. Popa (Romania)
DIABETES MANAGEMENT: LESSONS FROM
AROUND THE GLOBE ROMANIA
4.9 million deaths per year Intersects with all US$612 billion
dimensions of
50% of deaths under 60 development 11% of worldwide healthcare
years of age expenditure
Agenda
Prediabetes
16.5%
Known diabetes
9.2%
Diabetes
11.6%
NGT
71.9%
Unknown diabetes
2.4%
ROMANIA at a glance - PREDATORR 2013
DIABETES
Diabetes in Romania (20-79 years))
Adult Romanian population 15097473
(20-79 years)
Number of people with diabetes 1752000
Age- and sex-adjusted prevalence of 11.6%
diabetes
Undiagnosed cases 362340
(unknown diabetes mellitus UKDM)
Age- and sex-adjusted prevalence of UKDM 2.4%
Diabetes worldwide
(Adults 20-79 years); Source: IDF Diabetes Atlas Sixth Edition 2014
Top 10 countries/territories for prevalence (20-79 years)
2013 and 2035
Romania at glance
PREDATORR 2013
Romania
1.752 million
Romania
11.6%
Spain 2012 13.8%
Portugal 2010 11.7%
(Adults 20-79 years)
Source: IDF Diabetes Atlas Sixth Edition 2014
Diagnosed and undiagnosed diabetes among
people aged 20 years or older, United States, 2012
Source: 20092012 National Health and Nutrition Examination Survey estimates applied to 2012 U.S. Census data
ROMANIA at a glance - PREDATORR 2013
Prevalence of impaired glucose regulation by sex and age groups
50,4% 49,3%
35,5%
29,4%
11,5% 8,1%
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
ROMANIA at a glance - PREDATORR 2013
Prevalence of DIABETES and PREDIABETES by age groups
22%
4,3%
13.3%
27,8%
3,2%
18,9% 17,7%
2.9%
10,1%
0,2% 6,9%
2,7%
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
ROMANIA at a glance - PREDATORR 2013
Prevalence of DIABETES and PREDIABETES by sex
13.6%
2,9%
9.8%
1,9% 16,7%
16,3%
10,7%
7,9%
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
ROMANIA at a glance - PREDATORR 2013
Prevalence of DIABETES by sex and age groups
24.3%
4,6% 20%
17%
4,1%
4,9%
10.2%
1,8% 19,7%
15,9%
3.5% 12,1%
0 2.4% 8,4%
0,5%
3,5%
1,9%
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
Prevalence (%) of people with diabetes by age
and sex, 2013
(Adults 20-79 years) Source: IDF Diabetes Atlas Sixth Edition 2013
ROMANIA at a glance - PREDATORR 2013
PREDIABETES
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
Prediabetes worldwide
Source: 20092012 National Health and Nutrition Examination Survey estimates applied to 2012 U.S. Census data
Gardete-Correia L et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010; 27: 87981
Soriguer F et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study. Diabetologia. 2012; 55:8893.
IDF Diabetes Atlas Sixth Edition 2013
ROMANIA at a glance - PREDATORR 2013
Prevalence of PREDIABETES by sex and age groups
29,3%
26,1%
18,5% 19,2%
8%
5,7%
Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes. 2015 in press
(available at http://onlinelibrary.wiley.com/doi/10.1111/1753-0407.12297/abstract)
Prevalence (%) of IGT (20-79 years) by age and sex,
2013
(Adults 20-79 years) Source: IDF Diabetes Atlas Sixth Edition 2013
Agenda
2% 2%
18% 13%
47% Diet
45%
Polytherapy
Bitherapy
Monotherapy
36% 38%
2%
AGI 1%
2%
DPP-IV INHIBITORS 0,4%
0,40%
GLP-1 AGONISTS 1%
0,10%
GLINIDES 1%
2014 2013
GLITAZONES 1%
Displaying categories >2%
Type of therapy,
Classes in bitherapy
35%
BIGUANIDES+SULPHONYLUREAS 39%
24%
BIGUANIDES+INSULINS 24%
12%
INSULINS+INSULINS 9%
9%
DPP-IV INHIBITORS+BIGUANIDES 6%
5%
SULPHONYLUREAS+INSULINS 5%
4%
BIGUANIDES+GLP-1 AGONISTS 1%
2%
BIGUANIDES+AGI 1%
2014 2013
Displaying categories >2%
Type of therapy,
Classes in polyherapy
31%
BIGUANIDES+SULPHONYLUREAS+INSULINS 29%
18%
BIGUANIDES+INSULINS+INSULINS 26%
10%
DPP-IV INHIBITORS+BIGUANIDES+SULPHONYLUREAS 13%
9%
AGI+BIGUANIDES+SULPHONYLUREAS 10%
6%
BIGUANIDES+GLP-1 AGONISTS+SULPHONYLUREAS 1%
5%
DPP-IV INHIBITORS+BIGUANIDES 1%
4%
BIGUANIDES+INSULINS 5%
2%
BIGUANIDES+AGI+INSULINS 1%
2%
BIGUANIDES+BIGUANIDES 1%
2%
BIGUANIDES+SULPHONYLUREAS+GLITAZONES 1%
2014 2013
Displaying categories >2%
Type of therapy
Brands
Brands in monotherapy Brands in bitherapy Brands in polytherapy
9%
20% LANTUS+DIAPREL+SIOFOR 6%
48% DIAPREL+SIOFOR 18%
SIOFOR 42% 6%
8% DIAPREL+SIOFOR+LEVEMIR 1%
9% LANTUS+SIOFOR 7%
DIAPREL 13% SIOFOR+AMARYL+LANTUS
5%
7% 12%
9% JANUVIA+SIOFOR 4%
METFOGAMMA 5%
11%
6%
JANUVIA+SIOFOR+AMARYL 4%
6% AMARYL+SIOFOR 11% 4%
LANTUS 4% SIOFOR+DIAPREL+JANUVIA 7%
4%
SIOFOR+LEVEMIR 4% 4%
4% SIOFOR+AMARYL+GLUCOBAY 5%
GLUCOPHAGE 4% 4%
DIAPREL+METFOGAMMA 4% 4%
4% GLUCOBAY+SIOFOR+DIAPREL 3%
GLURENORM 3% 4%
NOVOMIX 30+SIOFOR 4% 4%
3% JANUVIA+GLIBOMET 1%
metforminum 3% 3%
GLIBOMET 8% LEVEMIR+NOVORAPID+SIOFOR
3%
3%
2%
NOVOMIX 3% 2% 3%
LEVEMIR+NOVORAPID 2% LEVEMIR+AMARYL+SIOFOR 1%
2% 2%
AMARYL 3% SIOFOR+GLUCOBAY 1% BYDUREON+DIAPREL+SIOFOR
3%
2% 2% 2%
HUMALOG 2% LANTUS+APIDRA 1% BYETTA+DIAPREL+SIOFOR
2% 2% 2%
LEVEMIR 1% METFOGAMMA+LANTUS 1% SIOFOR+NOVORAPID+LANTUS 4%
2% 2% 2%
GLUCOBAY NOVORAPID+LANTUS 1% LANTUS+GLIBOMET 3%
1%
2% 2%
2% HUMALOG+LANTUS 1%
SIOFOR+LANTUS+APIDRA 2%
HUMULIN 1%
2% 2%
2% BYDUREON+SIOFOR AMARYL+METFOGAMMA+LANTUS 1%
JANUVIA 0,4% 2%
SIOFOR+APIDRA+LANTUS 1%
2014 2013
2014 2013 2014 2013
Those 101 general physicians who who enrolled the participants, filled in the
study questionnaires, and collected blood and urine samples from the participants